{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.4","upperLimit":"13.3","value":"6.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive nivolumab IV over 30-60 minutes on days 1 and 15 of cycles 1-4 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nNivolumab: Given IV","id":"OG000","title":"Treatment (Nivolumab)"}],"paramType":"MEDIAN","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"assessed at baseline, then every 8 weeks for the first 2 years, then every 12 weeks in year 3, until disease progression","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}